Yu Cao1, Xing Liu2, Ying Li2, Yao Lu2, Hua Zhong2, Weihong Jiang1, Alex F Chen1,2,3, Timothy R Billiar2,3, Hong Yuan1,2,3, Jingjing Cai4,5,6. 1. Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China. 2. The Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China. 3. Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4. Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China. caijingjing83@hotmail.com. 5. The Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China. caijingjing83@hotmail.com. 6. Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. caijingjing83@hotmail.com.
Abstract
BACKGROUND: The presence and severity of proteinuria is considered an important prognostic marker in patients with chronic kidney disease (CKD) and is associated with mortality and morbidity. Cathepsin L is highly expressed in the foot processes of podocytes in the kidney, which serves as an ultrafiltration barrier. Cathepsin L is also up-regulated in the setting of inflammation as a feature of CKD. Therefore, we postulated that proteinuria severity in CKD patients might correlate with increased serum levels of cathepsin L. METHODS AND RESULTS: In this retrospective observational study, a total of 135 patients diagnosed with CKD, 31 renal transplant patients and 48 healthy controls were included. The demographic characteristics and clinical indicators were analyzed. Serum cathepsin L activity was significantly higher in patients with CKD than in renal transplant recipients and healthy controls (P < 0.01). Patients with severe proteinuria had a higher cathepsin L activity compared to those with moderate or mild proteinuria (P < 0.01). Serum cathepsin L activity positively associated with age, body mass index, nitrite level, neutrophil count, high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide, high-mobility group box-1 protein (HMGB1) and 24-h proteinuria. In the ROC analysis, the sensitivity of cathepsin L activity in diagnosis of moderate and heavy is 0.86 and the specificity is 0.73. Moreover, CKD patients with higher cathepsin L activity had a significantly higher hospital admission rate. The data also showed patients with statin administration present significantly lower cathepsin L activity (P < 0.01), hs-CRP (P < 0.01), HMGB1 (P < 0.01) and proteinuria (P < 0.01) compared to non-statin treatment group. CONCLUSION: This study revealed that serum cathepsin L activity is significantly elevated in CKD patients and its level correlates with the severity of proteinuria as well as prognosis, suggesting that serum cathepsin L may serve as a potential biomarker for CKD. Further prospective study is needed to explore its clinical implications in the future.
BACKGROUND: The presence and severity of proteinuria is considered an important prognostic marker in patients with chronic kidney disease (CKD) and is associated with mortality and morbidity. Cathepsin L is highly expressed in the foot processes of podocytes in the kidney, which serves as an ultrafiltration barrier. Cathepsin L is also up-regulated in the setting of inflammation as a feature of CKD. Therefore, we postulated that proteinuria severity in CKDpatients might correlate with increased serum levels of cathepsin L. METHODS AND RESULTS: In this retrospective observational study, a total of 135 patients diagnosed with CKD, 31 renal transplant patients and 48 healthy controls were included. The demographic characteristics and clinical indicators were analyzed. Serum cathepsin L activity was significantly higher in patients with CKD than in renal transplant recipients and healthy controls (P < 0.01). Patients with severe proteinuria had a higher cathepsin L activity compared to those with moderate or mild proteinuria (P < 0.01). Serum cathepsin L activity positively associated with age, body mass index, nitrite level, neutrophil count, high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide, high-mobility group box-1 protein (HMGB1) and 24-h proteinuria. In the ROC analysis, the sensitivity of cathepsin L activity in diagnosis of moderate and heavy is 0.86 and the specificity is 0.73. Moreover, CKDpatients with higher cathepsin L activity had a significantly higher hospital admission rate. The data also showed patients with statin administration present significantly lower cathepsin L activity (P < 0.01), hs-CRP (P < 0.01), HMGB1 (P < 0.01) and proteinuria (P < 0.01) compared to non-statin treatment group. CONCLUSION: This study revealed that serum cathepsin L activity is significantly elevated in CKDpatients and its level correlates with the severity of proteinuria as well as prognosis, suggesting that serum cathepsin L may serve as a potential biomarker for CKD. Further prospective study is needed to explore its clinical implications in the future.
Authors: Frank M Sacks; Michel P Hermans; Paola Fioretto; Paul Valensi; Timothy Davis; Edward Horton; Christoph Wanner; Khalid Al-Rubeaan; Ronnie Aronson; Isabella Barzon; Louise Bishop; Enzo Bonora; Pongamorn Bunnag; Lee-Ming Chuang; Chaicharn Deerochanawong; Ronald Goldenberg; Benjamin Harshfield; Cristina Hernández; Susan Herzlinger-Botein; Hiroshi Itoh; Weiping Jia; Yi-Der Jiang; Takashi Kadowaki; Nancy Laranjo; Lawrence Leiter; Takashi Miwa; Masato Odawara; Ken Ohashi; Atsushi Ohno; Changyu Pan; Jiemin Pan; Juan Pedro-Botet; Zeljko Reiner; Carlo Maria Rotella; Rafael Simo; Masami Tanaka; Eugenia Tedeschi-Reiner; David Twum-Barima; Giacomo Zoppini; Vincent J Carey Journal: Circulation Date: 2013-12-18 Impact factor: 29.690
Authors: Mariadelina Simeoni; Ramona Nicotera; Maria Colao; Maria Lucia Citraro; Elena Pelagi; Annamaria Cerantonio; Nicola Comi; Giuseppe Coppolino; Giorgio Fuiano Journal: Int Urol Nephrol Date: 2015-10-05 Impact factor: 2.370
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; David W Johnson; Vlado Perkovic; Jorgen Hegbrant; Giovanni F M Strippoli Journal: Cochrane Database Syst Rev Date: 2014-05-31
Authors: Pasquale Cocchiaro; Valeria De Pasquale; Rossella Della Morte; Simona Tafuri; Luigi Avallone; Anne Pizard; Anna Moles; Luigi Michele Pavone Journal: Front Cell Dev Biol Date: 2017-12-19
Authors: Caio P Gomes; Danilo E Fernandes; Fernanda Casimiro; Gustavo F da Mata; Michelle T Passos; Patricia Varela; Gianna Mastroianni-Kirsztajn; João Bosco Pesquero Journal: Front Cell Infect Microbiol Date: 2020-12-08 Impact factor: 5.293
Authors: Luise Hassler; Fabiola Reyes; Matthew A Sparks; Paul Welling; Daniel Batlle Journal: Clin J Am Soc Nephrol Date: 2021-06-14 Impact factor: 8.237